Aeryon Labs Closes $60 Million Investment from Summit Partners

Aeryon Labs Inc., the premier manufacturer of small unmanned aerial systems (sUAS) and mission control software, today announced that it has closed a $60 million investment from Summit Partners.

This investment will help the company realize its ambitious vision for the sUAS market, which sees widespread adoption across military, public safety and commercial operators worldwide.

Enterprise-grade sUAS (commonly known as drones) provide an easy-to-deploy, safe and cost-effective means to acquire mission-critical aerial intelligence for a variety of applications. According to analyst estimates, the sUAS market is rapidly expanding and is expected to approach $6 billion by 2020.

Ranked 7th as a 2014 Deloitte Technology Fast 50™ company and 14th in the North American Technology Fast 500™ ranking, Aeryon has experienced profitable organic growth and global expansion across its 9-year operating history, with customers in over 35 countries. The additional capital from Summit Partners will enable Aeryon to build upon this operational success and accelerate its expansion and delivery of additional capabilities to its core market segments.

"This is a significant milestone for Aeryon Labs," said Dave Kroetsch, the company's President and CEO and one of its principal founders. "It validates our technical lead in the market and our 'aviation not recreation' approach to building sUAS, which is quickly making Aeryon a first choice for utility inspectors, first responders and soldiers in the most demanding operational environments."

"Much of the Summit portfolio is comprised of founder-led companies, poised to take commanding positions in high-growth industries. We believe Aeryon exemplifies these characteristics," said Len Ferrington, a Managing Director at Summit who will join the Aeryon Labs Board of Directors. "The market for sUAS is rapidly expanding, and we believe that Aeryon is a best-of-breed provider that is well positioned to capitalize on those opportunities."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.